Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,087 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nevi and Melanomas Clear all
Completed Phase 2 Interventional

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

NCT06151847
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Biospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2, Lifileucel, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

NCT04109456
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
IN10018, Cobimetinib, Atezolizumab
Drug · Biological
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

NCT01127451
View directory record Official record
Conditions
Stage IIIC Melanoma, Stage IV Melanoma
Interventions
Denileukin diftitox
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Jul 24, 2026, 11:12 AM EDT
Completed No phase listed Observational

Melanoma Molecular Profiling Analysis

NCT00889980
View directory record Official record
Conditions
Melanoma
Interventions
Biospecimen banking
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00019994
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, aldesleukin, gp100 antigen, incomplete Freund's adjuvant
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

NCT00002854
View directory record Official record
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Jul 24, 2026, 11:12 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951
View directory record Official record
Conditions
Melanoma
Interventions
cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

NCT02360579
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Lifileucel
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

NCT00005961
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

NCT02404441
View directory record Official record
Conditions
Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer, Other Solid Tumors
Interventions
PDR001
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

NCT00450372
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
ADI-PEG-20, Pharmacology Studies
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Jul 24, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional Results available

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NCT03993379
View directory record Official record
Conditions
Solid Tumor, Unresectable or Metastatic Melanoma
Interventions
CX-072, Ipilimumab
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 24, 2026, 11:12 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134
View directory record Official record
Conditions
Melanoma
Interventions
Ceralasertib, Durvalumab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma

NCT00862901
View directory record Official record
Conditions
Breast Cancer, Skin Cancer
Interventions
CLIPT patch
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

NCT00327600
View directory record Official record
Conditions
Malignant Melanoma
Interventions
imexon, DTIC
Drug
Lead sponsor
AmpliMed Corporation
Industry
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Jul 24, 2026, 11:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

NCT02743611
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
Interventions
BPX-701, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Denver, Colorado • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jul 24, 2026, 11:12 AM EDT
Withdrawn Not applicable Interventional

Mohs and Immunofluorescence for Malignant Melanoma In Situ

NCT02306512
View directory record Official record
Conditions
Lentigo Maligna, Melanoma In Situ
Interventions
H&E, IHC MART-1, IF MART-1, IF cocktail
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00079144
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 peptide vaccine, aldesleukin, filgrastim, incomplete Freund's adjuvant, therapeutic autologous lymphocytes, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

NCT02423863
View directory record Official record
Conditions
Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
Interventions
Hiltonol
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 24, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional Results available

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

NCT00706992
View directory record Official record
Conditions
Melanoma
Interventions
ALVAC-MART-1 vaccine, MART-1:26-35(27L) peptide vaccine, Aldesleukin, autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, incomplete Freund's adjuvant
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Jul 24, 2026, 11:12 AM EDT
Completed No phase listed Observational

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

NCT00617799
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
aldesleukin, gene expression analysis, mutation analysis, flow cytometry
Biological · Genetic · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 24, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

NCT00026143
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
recombinant interleukin-12, recombinant interferon alfa, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jul 24, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional Results available

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

NCT01721603
View directory record Official record
Conditions
BRAFV600E Melanoma Patients
Interventions
Dabrafenib, Gamma Knife Radiosurgery, Trametinib
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 24, 2026, 11:12 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma

NCT00199342
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
KW-2871
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Birmingham, Alabama • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 24, 2026, 11:12 AM EDT